In his latest interview, Devang Mehta of Anand Rathi sent a no-holds-barred buy call on Suven Life Sciences. He pointed out that Suven is “an excellent high-growth, high-margin business” and it has “a superb balance sheet and good return ratios”. He added that Suven has a “huge monetisation opportunity for one of its molecules called SUVN-502”. Suven can be a “dark horse”, Devang said and projected a “conservative” price target of Rs 336 for the stock.
Well, today Suven surged nearly 20%, bringing joy to all those who had acted on Devang Mehta’s call.
Anand Rathi has also issued an Initiating Coverage report on Suven Life Sciences where the entire nitty-gritty of the Company is explained in detail.
It must also be noted that Suven Life Sciences is one of the seven stocks conferred with the privilege of being a “potential 100-bagger” stock by the Motilal Oswal 19th Wealth Creation Study Report.
We must also not forget to pay tribute to Vineeta Mahnot of Hem Securities who was one of the first spotters of the opportunity in Suven. Vineeta recommended a buy in November 2013 when the stock was available at a throwaway valuation of Rs. 46. Her followers are sitting on mind-boggling gains of 471%.